Published May 13, 2021 Dollar Photo Club
The instructions for making a human are long and complicated. They involve over 3 billion sets of microscopic letters, so tightly coiled that, if unwound, they would be taller than the average person.
The daunting task of reading these instructions involves a type of protein called transcription factors. But, while integral to life, these proteins can also cause disease when they mutate or malfunction.
For drug developers, transcription factors are an attractive target. Every biotech company that I ve been a part of has been interested in at least one or two, said Abbie Celniker, a well-known industry veteran and a partner at the healthcare investment firm Third Rock Ventures. That s been true since the early 1990s, according to Celniker, who s worked at high-profile companies including Novartis, Millennium Pharmaceuticals and Genentech.
Eventide Announces Promotion of Harry Nelson to Chief Operating Officer
News provided by
Share this article
Share this article
BOSTON, May 7, 2021 /PRNewswire/ Eventide is pleased to announce the promotion of Harry Nelson to Chief Operating Officer from his current position of Director of Distribution for Eventide. As Chief Operating Officer, he is responsible for leading Eventide s corporate performance and operations as well as several business development functions, including managing the relationships between Eventide and intermediaries.
Prior to joining Eventide in 2017, Mr. Nelson was President of GuideStone Capital Management, LLC. Before that, he served in business development roles at GuideStone and Golden Capital Management. He holds the Certified Investment Management Analyst certification administered by Investment Management Consultants Association and taught, in conjunction with the Wharton School of Business, at the University of Pennsylvania. He earned a B.A. i
Eventide Asset Management Wins Two 2021 Refinitiv Lipper Fund Awards
News provided by
Share this article
Share this article
BOSTON, March 11, 2021 /PRNewswire/ Eventide is pleased to announce that it is being honored with two 2021 Refinitiv Lipper Fund Awards in the United States.
The following two Eventide Funds are being recognized for their consistently strong, risk-adjusted performance relative to their peers over the given time frames:
Eventide Healthcare & Life Sciences Fund (
ETIHX), Best Health/Biotechnology Fund Over 3 Years.
Eventide Gilead Fund (
ETILX), Best Mid-Cap Growth Fund Over 10 Years. This award is a testament to our emphasis on pursuing excellence while staying true to our purpose of loving our neighbors through the way we invest, said Robin John, CEO of Eventide Asset Management. During a year marked with uncertainty, our team has remained resilient and persistent in seeking to provide excellent service for our clients.